A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

"Guarantor of the article: Gary R. Lichtenstein, MD.: Specific author contributions: Design and conduct of clinical trials contributing data to these pooled analyses: Gary R. Lichtenstein, Paul Rutgeerts, William J. Sandborn, Bruce E. Sands, and Robert H. Diamond; data collection and analysis: Robert H. Diamond, Linda Tang, Jennifer Montello, and Freddy Cornillie; and all authors provided critical content review and final approval of this manuscript.: Financial support: Funding for the clinical trials contributing data to these pooled analyses was provided by Janssen Research & Development, a Johnson & Johnson (J&J) pharmaceutical company.: Potential competing interests: Dr Lichtenstein has received research grants and/or has served as a consultant for Abbott Corporation, Alaven, Bristol-Myers Squibb, Janssen, Elan, Ferring, Meda Pharmaceuticals, Merck/Schering-Plough, Millennium Pharmaceuticals, Pfizer Pharmaceuticals, Proctor and Gamble, Prometheus Laboratories, Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, UCB, Warner Chilcotte, and Wyeth. Professor Rutgeerts has received research support from Janssen, Merck/Schering-Plough, UCB, and Abbott Laboratories, as well as consulting and/or speaking honoraria from Janssen, Merck/Schering-Plough, UCB, Abbott Laboratories, Elan-Biogen, NovImmune, Italfarmako, Bristol-Myers Squibb, Millennium Pharmaceuticals, Tillots, Glaxo SmithKline, and ChemoCentryx. Dr Sandborn has received has received consulting fees and research support from Abbott Laboratories, Janssen, and UCB Pharma, as well as consulting fees from Merck/Schering-Plough. Dr Sands has received consulting fees from Abbott Immunology, Axcan Pharma, Avaxia Biologics, Bristol-Myers Squibb, Elan Pharmaceuticals, Emmi Solutions, Janssen, Glaxo Wellcome SmithKline, Millennium Pharmaceuticals/Takeda, Novartis Pharmaceuticals, Pfizer, Prometheus Laboratories, and owns common stock in Avaxia Biologics, a company that is not publicly traded. Professor Colombel has received consulting fees and has participated in continuing medical education events supported by unrestricted educational grants from Janssen and Merck/Schering-Plough. Dr Diamond and Linda Tang are employed by Janssen Research & Development, a J&J pharmaceutical company. Jennifer Montello is an employee of J&J. Freddy Cornillie is an employee of Janssen Biologics BV, a J&J pharmaceutical company."

"Financial support : Funding for the clinical trials contributing data to these pooled analyses was provided by Janssen Research & Development, a Johnson & Johnson (J&J) pharmaceutical company."